In an industry as focused on people as healthcare, companies must not only dedicate themselves to the consistent discovery of new and innovative medicines and treatments, they need also demonstrate a solid commitment to improving the quality of patients’ lives. For Eli Lilly and Company, a pharmaceutical multinational with a 145-year history, such a commitment…

The COVID-19 pandemic has presented Taiwan with a unique opportunity to gain a lead in the Asia-Pacific’s new drug discovery sector. But for Taiwan to excel, the biomedical industry is calling for a change of policies. Taiwan has been striving for many years to position itself as a regional biomedical hub and an attractive location…

During the pandemic, those previously unaware of the intricate distribution process of vaccines and pharmaceuticals learned a great deal about the complexity of the business, which involves cold-chain management and other massive logistical challenges. Zuellig Pharma plays a pivotal role in this process in Asia. The company was founded a century ago in the Philippines…

Although a newcomer to the healthcare scene, global pharmaceutical company Viatris, formed in November 2020 through a merger of Upjohn, a legacy division of Pfizer, and Mylan, already has a sizable industry footprint. By combining the two complementary businesses, the merger has accelerated their ability to serve patients and expanded their resources across more than…

The company hopes to benefit citizens and shed new light on the treatment of cancer. Pfizer Taiwan and the National Health Research Institutes (NHRI), along with two other partnering companies, recently signed a precision medicine cooperation alliance agreement, officially launching a joint initiative to develop precision cancer treatments in Taiwan. The agreement commits all parties…

Taiwan has been under the international spotlight since its early intervention in the COVID-19 crisis, and its comprehensive virus-prevention measures have made it one of the world’s few safe havens during the pandemic. The increased visibility of this island powerhouse has also drawn attention to its strengths in the area of healthcare, including clinical research….

Finding effective solutions to the world’s health issues requires novel, holistic approaches and collaborative ingenuity. Healthcare companies must therefore increasingly shift their focus to the research and development of medical technologies, biopharmaceuticals, and innovative therapies to treat conditions and diseases that are difficult or nearly impossible to tackle using traditional medicines. Such a reality is…

For GlaxoSmithKline Taiwan (GSK) General Manager Mick Stanley, a company is only as successful and progressive as the people behind it. He cites the multinational pharmaceutical firm’s ability to balance performance with pursuing solutions that positivity impact patients and public health as one of the main reasons he’s stayed with them for the last 20…

2020 has been a big year for American biopharmaceutical company Bristol Meyers Squibb (BMS). Its blockbuster US$74 billion acquisition last year of biotech firm Celgene positions BMS as the number one oncology hematology company worldwide. What this merger means for the Taiwan BMS affiliate is not only a portfolio expansion, doubling the number of key…

An annual report lists Taiwan-related trade issues being followed in Washington. Early each year, the Office of the U.S. Trade Representative (USTR) releases a country-by-country Report on Foreign Trade Barriers. The nine-page Taiwan section for 2020 provides a concise statement of the main areas of U.S.-government concern regarding elements of the bilateral trade relationship. Taiwan’s…